Stock ALMKT MAUNA KEA TECHNOLOGIES
Add to a list
To use this feature you must be a member
Log inSign up

News Mauna Kea Technologies

Equities

ALMKT

FR0010609263

Market Closed - Euronext Paris
Other stock markets
 11:13:37 2024-04-16 am EDT 		5-day change 1st Jan Change
0.393 EUR -0.76% Intraday chart for Mauna Kea Technologies -2.00% -16.56%
Apr. 03 Mauna Kea: first Italian center for Cellvizio CF
Mar. 27 Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Mauna Kea: first Italian center for Cellvizio
CF
Mauna Kea Technologies Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
BU
Mauna Kea Technologies : Announces the Opening of the First Italian Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
PU
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio
BU
Mauna Kea Technologies Partners with V7 to Develop Innovative AI Applications with Cellvizio
CI
Mauna Kea: partnership with Metrodora Institute in the USA
CF
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
BU
Mauna Kea Technologies Partners with Metrodora to Create First U.S. Center of Excellence for the Use of Cellvizio® to Identify and Treat Food Intolerance in Adults
CI
MAUNA KEA TECHNOLOGIES REPORTS FULL YEAR 2023 SALES OF EUR10.5M, UP +42% VS 2022
AQ
Mauna Kea: Johnson & Johnson Innovation below 20% threshold
CF
Mauna Kea Technologies to Receive EUR6 Million Investment from Telix Pharmaceuticals
MT
Mauna Kea: share price surges as Telix acquires 19% stake
CF
Telix Pharmaceuticals Limited and Mauna Kea Technologies SA to Expand Collaboration in Urologic Oncology Surgery
CI
Mauna Kea Technologies SA announced that it expects to receive ?6 million in funding from Telix Pharmaceuticals Limited
CI
Mauna Kea Technologies : Inside Information / Other news releases
PU
Mauna Kea Technologies Announces First Patient Enrolled in the Pivotal CLEVER Clinical Trial in Peripheral Lung Cancer
CI
Mauna Kea Technologies Reports Sales Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Mauna Kea Technologies Announces the Publication of Positive Results of a Randomized Controlled Trial in the Field of Interstitial Lung Disease
AQ
Mauna Kea Technologies SA Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Mauna Kea Technologies and Endoscopy Institute of Hawaii Achieve 1,200 Procedure Milestone
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALMKT Stock
  4. News Mauna Kea Technologies